BLSM vs CBIO: fair value comparison
BlossomHill Therapeutics, Inc. and Crescent Biopharma, Inc. · Updated 2026-10-19
BLSM has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. CBIO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, BLSM currently ranks higher by quality score.
| BLSM | CBIO | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $13.94 | $11.84 |
| 12-month range | $13.94–$18.99 | $8.94–$26.98 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #225 of 301 Healthcare | #226 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | — | Contracting |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | — | Mixed |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: BLSM fair value analysis · CBIO fair value analysis